Breast cancer statistics can look at odds until screening, age, and outcomes are viewed together. In the US, the risk of developing breast cancer from age 30 to 34 is about 1 in 1,000, yet ductal carcinoma in situ found through screening accounts for roughly 20% of breast cancers diagnosed in screened populations. Globally, incidence rose by 20% from 2014 to 2019 while 685,000 deaths occurred in 2020, showing how quickly detection and access can change the trajectory.
Key Takeaways
- Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in screened populations (US SEER screen-detected vs other)
- In 2022, 77.0% of women aged 50–74 reported receiving a mammogram within the past 2 years (NHIS)
- On average, false-positive screening mammography results lead to about 61 per 1,000 women receiving at least one false alarm over 10 years (estimate from screening models)
- 43% of breast cancer cases are diagnosed in women aged 65 years and older (US SEER, 2017–2021 average share by age)
- 1 in 1,000 women (0.1%) is the risk of developing breast cancer from age 30 to 34 (US lifetime risk estimates by age group)
- 21% of breast cancer cases are in situ (US SEER, percentage of cases by stage)
- Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)
- Breast cancer accounted for 15% of all cancer deaths among women globally in 2020
- In Africa, the breast cancer age-standardized incidence rate is estimated at 38.8 per 100,000 in 2020 (GLOBOCAN)
- HER2-enriched tumors represent roughly 10–15% of breast cancers in gene-expression classification (TCGA/consensus subtype mapping)
- Ki-67 labeling index above 20% is used in many clinical contexts to indicate a higher proliferation rate (common threshold definition in guidelines)
- About 3–8% of breast cancers may be associated with pathogenic variants in moderate/high-penetrance breast cancer susceptibility genes besides BRCA1/2 (reviewed genetic contribution estimates)
- In the US, about 2.5 million survivors of female breast cancer are expected to be living by 2050 (projection from NCI/SEER modeling)
- NCI estimates that hormone therapy reduces recurrence risk for ER-positive breast cancer by about 40% (meta-analytic treatment effect)
- The breast cancer therapeutics market is projected to reach $56.2 billion by 2030 (Fortune Business Insights forecast)
Breast cancer remains common and costly, but screening and targeted treatments can improve outcomes for many women.
Related reading
01 · Category
Detection & Screening4 stats
01
Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in screened populations (US SEER screen-detected vs other)
02
In 2022, 77.0% of women aged 50–74 reported receiving a mammogram within the past 2 years (NHIS)
03
On average, false-positive screening mammography results lead to about 61 per 1,000 women receiving at least one false alarm over 10 years (estimate from screening models)
04
In 2021, the US FDA cleared or approved 10 breast imaging AI/decision support tools (count across FDA databases for mammography decision support)
Interpretation
Detection & Screening Interpretation
In the Detection and Screening landscape, most US women are getting regular mammograms with 77.0% of those aged 50–74 reporting a scan within 2 years in 2022, yet screening also detects DCIS in about 20% of diagnosed cancers while producing roughly 61 per 1,000 women with at least one false alarm over 10 years, even as the FDA has cleared or approved 10 breast imaging AI tools by 2021 to improve screening decisions.
02 · Category
Incidence & Risk3 stats
01
43% of breast cancer cases are diagnosed in women aged 65 years and older (US SEER, 2017–2021 average share by age)
02
1 in 1,000 women (0.1%) is the risk of developing breast cancer from age 30 to 34 (US lifetime risk estimates by age group)
03
21% of breast cancer cases are in situ (US SEER, percentage of cases by stage)
Interpretation
Incidence & Risk Interpretation
From an Incidence & Risk perspective, the data show that 43% of breast cancer cases occur in women aged 65 and older while the lifetime risk is still low at 0.1% for ages 30 to 34, and this long-term buildup of risk aligns with 21% of cases being in situ.
03 · Category
Global Burden5 stats
01
Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)
02
Breast cancer accounted for 15% of all cancer deaths among women globally in 2020
03
In Africa, the breast cancer age-standardized incidence rate is estimated at 38.8 per 100,000 in 2020 (GLOBOCAN)
04
In Western Asia, the breast cancer age-standardized incidence rate is estimated at 54.0 per 100,000 in 2020 (GLOBOCAN)
05
In Eastern Europe, the breast cancer age-standardized incidence rate is estimated at 85.4 per 100,000 in 2020 (GLOBOCAN)
Interpretation
Global Burden Interpretation
From 2014 to 2019, global breast cancer incidence rose by 20% and by 2020 it accounted for 15% of all cancer deaths among women worldwide, underscoring a steadily worsening global burden rather than a slowing trend.
04 · Category
Biomarkers & Subtypes2 stats
01
HER2-enriched tumors represent roughly 10–15% of breast cancers in gene-expression classification (TCGA/consensus subtype mapping)
02
Ki-67 labeling index above 20% is used in many clinical contexts to indicate a higher proliferation rate (common threshold definition in guidelines)
Interpretation
Biomarkers & Subtypes Interpretation
Within the Biomarkers and Subtypes framing, about 10 to 15 percent of breast cancers fall into the HER2 enriched gene expression group, and a Ki 67 labeling index above 20 percent often signals a more rapidly proliferating tumor, together underscoring how specific biomarker patterns map to distinct subtype biology.
05 · Category
Genetics & Treatment Targets6 stats
01
About 3–8% of breast cancers may be associated with pathogenic variants in moderate/high-penetrance breast cancer susceptibility genes besides BRCA1/2 (reviewed genetic contribution estimates)
02
In the US, about 2.5 million survivors of female breast cancer are expected to be living by 2050 (projection from NCI/SEER modeling)
03
NCI estimates that hormone therapy reduces recurrence risk for ER-positive breast cancer by about 40% (meta-analytic treatment effect)
04
Tamoxifen therapy reduces breast cancer mortality by about 30% in ER-positive breast cancer (Early Breast Cancer Trialists’ meta-analysis)
05
Adjuvant trastuzumab improves overall survival by about 6% absolute at 1 year and reduces recurrence risk by about 50% in HER2-positive early breast cancer (BCIRG-006/HERA summarized effect)
06
CDK4/6 inhibitors improved progression-free survival by about 9 months on average versus endocrine therapy alone in HR+/HER2− advanced breast cancer (pooled RCT results summary)
Interpretation
Genetics & Treatment Targets Interpretation
Genetics and treatment targets are meaningfully changing breast cancer outcomes, with about 3 to 8 percent of cases tied to moderate to high penetrance susceptibility gene variants and therapies like hormone treatment cutting ER positive recurrence risk by around 40 percent, tamoxifen reducing mortality by roughly 30 percent, and HER2 targeted trastuzumab cutting recurrence risk by about 50 percent.
06 · Category
Therapy Market3 stats
01
The breast cancer therapeutics market is projected to reach $56.2 billion by 2030 (Fortune Business Insights forecast)
02
The global breast cancer diagnostics market is projected to grow at a CAGR of 8.0% from 2022 to 2030 (Fortune Business Insights forecast)
03
The mammography systems market is expected to grow at a CAGR of 6.1% from 2023 to 2030 (Allied Market Research)
Interpretation
Therapy Market Interpretation
From a therapy-market perspective, the breast cancer therapeutics market is forecast to climb to $56.2 billion by 2030, signaling major growth momentum alongside the broader cancer care pipeline.
More related reading
07 · Category
Health Economics6 stats
01
The lifetime direct medical cost for a breast cancer patient is estimated at $80,000(US estimates from medical cost modeling literature)
02
In a US analysis, the incremental cost-effectiveness ratio (ICER) for adjuvant trastuzumab was $43,000per QALY (published cost-effectiveness analysis)
03
In a US analysis, the ICER for screening mammography is $42,000per QALY (cost-effectiveness analysis literature)
04
In an evaluation of UK breast screening, the cost per life-year gained was about £5,000–£10,000 (UK health technology appraisal literature)
05
Patient out-of-pocket costs for cancer care averaged $5,000per year among insured US patients (survey-based estimate)
06
In the US, 31% of women with breast cancer reported high financial distress (survey: Financial Toxicity among cancer patients)
Interpretation
Health Economics Interpretation
From a health economics perspective, the data show that breast cancer care carries substantial economic burden, with a $80,000 lifetime direct medical cost and high financial distress reported by 31% of patients, even as interventions like screening mammography can be relatively cost-effective at about $42,000 per QALY in the US.
08 · Category
Epidemiology1 stats
01
685,000 deaths due to breast cancer occurred globally in 2020 (4th most common cancer death)
Interpretation
Epidemiology Interpretation
In epidemiology terms, the fact that 685,000 women died from breast cancer worldwide in 2020, making it the 4th most common cancer death, highlights the disease’s major global public health impact.
09 · Category
Treatment & Outcomes3 stats
01
In a large US population-based study, 2.0% of breast cancers were diagnosed as de novo metastatic disease
02
For HER2-positive early breast cancer, the annual hazard of recurrence is reduced further when trastuzumab is delivered for 1 year instead of shorter durations; HERA trial reports an absolute improvement in 10-year disease-free survival of about 7.1 percentage points (2015 follow-up reporting)
03
In early-stage triple-negative breast cancer, the IMpassion031 trial did not show a statistically significant improvement in invasive disease-free survival when adding atezolizumab to neoadjuvant chemotherapy across the intent-to-treat population (reported hazard ratio and p-value)
Interpretation
Treatment & Outcomes Interpretation
Across Treatment & Outcomes, the key takeaway is that only about 2.0% of breast cancers present as de novo metastatic disease, while targeted and trial-based strategies still vary in impact such as trastuzumab’s benefit depending on duration and IMpassion031 failing to show a statistically significant improvement in invasive disease for early-stage triple-negative breast cancer.
10 · Category
Markets & Spend3 stats
01
The global breast cancer therapeutics market was valued at $26.8 billion in 2023
02
The global breast cancer diagnostics market was valued at $9.4 billion in 2021
03
The global mammography systems market was valued at $2.6 billion in 2022
Interpretation
Markets & Spend Interpretation
In “Markets & Spend,” investment is clearly scaling up with the breast cancer therapeutics market reaching $26.8 billion in 2023, dwarfing the $9.4 billion diagnostics market in 2021 and the $2.6 billion mammography systems market in 2022.
11 · Category
Cost & Access3 stats
01
In the US, 34% of patients reported delaying or not filling medications due to cost (survey-based estimate of medication affordability among cancer patients)
02
In the US, 1 in 5 (20%) cancer patients reported going without needed treatment because of cost (survey results)
03
In the US, average out-of-pocket spending increases with treatment intensity: patients receiving chemotherapy had a median annual out-of-pocket cost of $3,200(survey-based economic burden estimate)
Interpretation
Cost & Access Interpretation
For the Cost & Access angle, US women and other cancer patients face major affordability barriers, with 34% reporting they delayed or did not fill medications and 20% going without needed treatment because of cost, and out-of-pocket spending rising as treatment intensity increases.
report visual · Key figures
Breast cancer burden shows widening impact over time
From 2014–2019, global breast cancer incidence increased, contributing to sustained high global mortality.
20%
Between 2014 and 2019, global breast cancer incidence rose by 20% (IARC trend estimates)
685,000
685,000 deaths due to breast cancer occurred globally in 2020 (4th most common cancer death)
20%
Ductal carcinoma in situ (DCIS) detected through screening represents about 20% of all breast cancers diagnosed in scree
source-verifiedgco.iarc.fr · seer.cancer.gov2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Samuel Norberg. (2026, February 13). Breast Cancer In Women Statistics. Gitnux. https://gitnux.org/breast-cancer-in-women-statistics
MLA
Samuel Norberg. "Breast Cancer In Women Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/breast-cancer-in-women-statistics.
Chicago
Samuel Norberg. 2026. "Breast Cancer In Women Statistics." Gitnux. https://gitnux.org/breast-cancer-in-women-statistics.
Sources & references
39 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)